Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SML2101

Sigma-Aldrich

Fosamprenavir calcium

≥98% (HPLC)

Synonym(s):

Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate, GW433908

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H34N3O9PS · Ca
CAS Number:
Molecular Weight:
623.67
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

[O-]P(O[C@H](CN(CC(C)C)S(C1=CC=C(N)C=C1)(=O)=O)[C@@H](NC(O[C@@H]2COCC2)=O)CC3=CC=CC=C3)([O-])=O.[Ca+2]

InChI

1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1

InChI key

PMDQGYMGQKTCSX-HQROKSDRSA-L

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Fosamprenavir calcium is an HIV protease inhibitor anti-retroviral. It is a water soluble phosphate ester prodrug of amprenavir, the active agent.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML2101-5MG:
SML2101-BULK:
SML2101-VAR:
SML2101-25MG:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Lisa L Ross et al.
The open AIDS journal, 9, 38-44 (2015-07-15)
Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)-naïve and ART-experienced patients
Paola Nasta et al.
HIV clinical trials, 17(3), 96-108 (2016-04-30)
Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection. A retrospective multicohort analysis was conducted. Subjects from three European cohorts who started FPV/r or lopinavir/ritonavir (LPV/r) as a comparator contributed data

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service